Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by Artisan Partners Limited Partnership

Artisan Partners Limited Partnership lowered its stake in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 2.1% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,893,681 shares of the company's stock after selling 125,185 shares during the quarter. Artisan Partners Limited Partnership owned about 9.88% of Twist Bioscience worth $273,879,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in Twist Bioscience by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company's stock worth $269,860,000 after purchasing an additional 189,791 shares during the last quarter. ARK Investment Management LLC grew its position in Twist Bioscience by 4.4% in the fourth quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company's stock worth $260,040,000 after acquiring an additional 237,772 shares in the last quarter. State Street Corp raised its position in Twist Bioscience by 19.9% during the third quarter. State Street Corp now owns 3,167,353 shares of the company's stock valued at $143,101,000 after purchasing an additional 526,028 shares during the period. Thrivent Financial for Lutherans lifted its stake in shares of Twist Bioscience by 54.6% in the 4th quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company's stock valued at $69,972,000 after purchasing an additional 532,040 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Twist Bioscience by 1.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company's stock worth $61,807,000 after purchasing an additional 26,145 shares during the period.

Remove Ads

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Wolfe Research began coverage on Twist Bioscience in a research report on Friday, December 13th. They issued an "outperform" rating and a $60.00 price target for the company. Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. JPMorgan Chase & Co. raised their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a research note on Tuesday, February 4th. Barclays set a $58.00 target price on Twist Bioscience and gave the company an "overweight" rating in a research note on Monday, February 3rd. Finally, Robert W. Baird boosted their price objective on Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, Twist Bioscience presently has a consensus rating of "Moderate Buy" and a consensus price target of $54.40.

Twist Bioscience Stock Down 1.9 %

NASDAQ:TWST traded down $0.77 during mid-day trading on Monday, reaching $39.59. The company's stock had a trading volume of 331,396 shares, compared to its average volume of 938,057. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a 1 year low of $27.41 and a 1 year high of $60.90. The stock has a fifty day moving average of $45.15 and a 200-day moving average of $45.37. The firm has a market capitalization of $2.36 billion, a PE ratio of -11.71 and a beta of 2.15.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.09. The firm had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business's revenue for the quarter was up 24.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.75) EPS. Equities research analysts forecast that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Robert Chess sold 5,000 shares of Twist Bioscience stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $50.00, for a total value of $250,000.00. Following the completion of the sale, the director now directly owns 16,641 shares in the company, valued at $832,050. This trade represents a 23.10 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Paula Green sold 1,259 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $62,131.65. Following the transaction, the senior vice president now owns 132,014 shares in the company, valued at $6,514,890.90. The trade was a 0.94 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 33,799 shares of company stock worth $1,593,944 in the last 90 days. 3.01% of the stock is owned by corporate insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.